Matinas BioPharma Holdings, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Matinas BioPharma Holdings, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, is 1.6 times its market value (net cash). Higher than 93% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 100%
Sales fell 100% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-100% / -84%In 3 years sales changed by -100% while total assets changed by -84%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-10.1×Operating cash was negative last year, while some debt falls due within a year.
Higher than 54% of Healthcare companies in United States.
Cash Cushion Ratio
1.6× cashCash, after subtracting all debt, is 1.6 times its market value (net cash).
Higher than 93% of Healthcare companies in United States.
Tangible Assets Ratio
69%Of every $100 the company owns, $69 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 63% of Healthcare companies in United States.
Tangible Net Worth Ratio
53%Of every $100 of net worth, $53 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 50% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Matinas BioPharma Holdings, Inc. made a loss over the last year. Matinas BioPharma Holdings, Inc. owes $0.47 for every $1 it owns. Matinas BioPharma Holdings, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossMatinas BioPharma Holdings, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.93The share price is 0.93 times Matinas BioPharma Holdings, Inc.'s book value per share, lower than 80% of Healthcare companies in United States.
Market cap
$2 MThe total market value of all of Matinas BioPharma Holdings, Inc.'s shares at today's price (share price × number of shares), smaller than almost all Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$2 MWhat Matinas BioPharma Holdings, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.84Net worth divided by the number of shares. The share price of $1.71 is 0.9 times this, which is the P/B above.
Return on equity (ROE)
-141.2%Matinas BioPharma Holdings, Inc. lost 141.2% of its shareholders' money over the last year, lower than 79% of Healthcare companies in United States.
Owes vs Owns
0.47×Matinas BioPharma Holdings, Inc. owes $0.47 for every $1 it owns (low), higher than 53% of Healthcare companies in United States.
Dividend yield
NoneMatinas BioPharma Holdings, Inc. does not currently pay a dividend.
Profit growth
LossMatinas BioPharma Holdings, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashMatinas BioPharma Holdings, Inc. held $3 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Matinas BioPharma Holdings, Inc.: $2 M ÷ $2 M (30 Jun 2026) = 0.9.
What is Matinas BioPharma Holdings, Inc.'s return on equity?
Matinas BioPharma Holdings, Inc. lost 141.2% of its shareholders' money over the last year, lower than 79% of Healthcare companies in United States.
How much does Matinas BioPharma Holdings, Inc. owe compared with what it owns?
Matinas BioPharma Holdings, Inc. owes $0.47 for every $1 it owns (low), higher than 53% of Healthcare companies in United States.
Does Matinas BioPharma Holdings, Inc. pay a dividend?
No. Matinas BioPharma Holdings, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.